MiMedx Group
Manufacturing · Georgia, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1775 W Oak Commons Ct, Marietta, Georgia...Phone Number
(770) 651-9100Website
www.mimedx.comRevenue
$389.4 MillionStock Symbol
MDXGIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
6
1
1
1
1
1
About MiMedx Group
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The companys proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair.Read more
MiMedx Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MiMedx Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if MiMedx Group has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at MiMedx Group
Product Launch: Get notified when MiMedx Group launches new products
Earning: See what the market has to say on MiMedx Group recently announced quarterly report
Click to see if MiMedx Group had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
MiMedx Group, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MiMedx Group has new funding data
Check out if MiMedx Group is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined MiMedx Group as Masked Content
Find more new buyers
Compare Similar Companies to MiMedx Group
Compare insights from companies similar to MiMedx Group, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
MiMedx Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
MiMedx Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about MiMedx Group.
MiMedx Group financials insights
Gather financial insights about MiMedx Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Debt
$1.4M
2019
Debt
$75M
2020
Other Financing Round
$150M
MiMedx Group Tech Stack
A closer look at the technologies used by MiMedx Group
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Open Position
Person-Based
Executive Move
Executive Moves, Board of Directors
Person-Based
Compensation & Benefits, HR Operations
MiMedx Group News & Media
MIMEDX Announces Second Quarter 2026 Operating & Financial Results
Reports Second Quarter Net Sales of $64 MillionMIMEDX to Acquire Sanara MedTech
Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical SubspecialtiesMIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29
MARIETTA, Ga., July 20, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, July 29, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.MiMedx (NASDAQ: MDXG) awards 50913 restricted shares to director - Stock Titan
MiMedx director James L. Bierman receives 50,913 restricted shares at $3.64, vesting after 12 months or the next shareholder meeting, lifting his holdings to 263,684 shares.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding MiMedx Group
Sign Up For FreeTo access detailed company insights
MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The companys proprietary processing method... Read More
